Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis | MicrobiomeTrials← Back to trialsNCT03963375
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
CompletedPHASE4INTERVENTIONAL
Trial Details
Start: 2019-10-28Est. Completion: 2025-05-27
Enrollment target: 47 participants Locations- Washington University School of Medicine, St Louis, Missouri, United States
- Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Other microbiome trials you might be interested in
Multiple Sclerosis
The proposed study is a parallel-group randomized controlled trial (RCT) designed to establish the behavioral mechanism …
Chicago, United StatesEst. completion Oct 1, 2028
Multiple Sclerosis (MS) Primary Progressive
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicente…
Pheonix, United StatesEst. completion Jun 2030
Recruiting
Lennox Gastaut SyndromeDravet SyndromeTuberous Sclerosis Complex
This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol …
Little Rock, United StatesEst. completion Aug 1, 2027